OSE IMMUNO (OSE.PA) Stock Fundamental Analysis
EPA:OSE - FR0012127173 - Common Stock
6.13 EUR
-0.04 (-0.65%)
Taking everything into account, OSE scores 6 out of 10 in our fundamental rating. OSE was compared to 74 industry peers in the Biotechnology industry. OSE has an excellent financial health rating, but there are some minor concerns on its profitability. OSE is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
OSE had positive earnings in the past year.
OSE had a positive operating cash flow in the past year.
In the past 5 years OSE reported 4 times negative net income.
OSE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
OSE has a Return On Assets of 30.21%. This is amongst the best in the industry. OSE outperforms 98.65% of its industry peers.
OSE's Return On Equity of 58.68% is amongst the best of the industry. OSE outperforms 97.30% of its industry peers.
Looking at the Return On Invested Capital, with a value of 30.99%, OSE belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.21% | ||
| ROE | 58.68% | ||
| ROIC | 30.99% |
ROA(3y)-5.73%
ROA(5y)-10.16%
ROE(3y)-31.94%
ROE(5y)-31.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OSE has a better Profit Margin (44.88%) than 95.95% of its industry peers.
Looking at the Operating Margin, with a value of 52.42%, OSE belongs to the top of the industry, outperforming 98.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.42% | ||
| PM (TTM) | 44.88% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so OSE is creating value.
Compared to 1 year ago, OSE has more shares outstanding
Compared to 5 years ago, OSE has more shares outstanding
OSE has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.52 indicates that OSE is not in any danger for bankruptcy at the moment.
OSE's Altman-Z score of 3.52 is fine compared to the rest of the industry. OSE outperforms 77.03% of its industry peers.
The Debt to FCF ratio of OSE is 0.95, which is an excellent value as it means it would take OSE, only 0.95 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.95, OSE belongs to the top of the industry, outperforming 94.59% of the companies in the same industry.
OSE has a Debt/Equity ratio of 0.60. This is a neutral value indicating OSE is somewhat dependend on debt financing.
OSE has a Debt to Equity ratio of 0.60. This is comparable to the rest of the industry: OSE outperforms 51.35% of its industry peers.
Even though the debt/equity ratio score it not favorable for OSE, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 0.95 | ||
| Altman-Z | 3.52 |
ROIC/WACC4.48
WACC6.91%
2.3 Liquidity
OSE has a Current Ratio of 3.46. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
OSE has a better Current ratio (3.46) than 68.92% of its industry peers.
A Quick Ratio of 3.46 indicates that OSE has no problem at all paying its short term obligations.
OSE has a Quick ratio of 3.46. This is in the better half of the industry: OSE outperforms 70.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 245.42% over the past year.
The Revenue has grown by 3646.52% in the past year. This is a very strong growth!
Measured over the past years, OSE shows a very strong growth in Revenue. The Revenue has been growing by 26.31% on average per year.
EPS 1Y (TTM)245.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.06%
Revenue 1Y (TTM)3646.52%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%-0.81%
3.2 Future
OSE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -42.26% yearly.
The Revenue is expected to grow by 10.24% on average over the next years. This is quite good.
EPS Next Y-82.85%
EPS Next 2Y-63.7%
EPS Next 3Y-42.26%
EPS Next 5YN/A
Revenue Next Year-47.32%
Revenue Next 2Y-20.24%
Revenue Next 3Y10.24%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 3.58, which indicates a rather cheap valuation of OSE.
Based on the Price/Earnings ratio, OSE is valued cheaper than 97.30% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.13. OSE is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 14.80, OSE is valued correctly.
83.78% of the companies in the same industry are more expensive than OSE, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of OSE to the average of the S&P500 Index (22.76), we can say OSE is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.58 | ||
| Fwd PE | 14.8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, OSE is valued cheaper than 97.30% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of OSE indicates a rather cheap valuation: OSE is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.9 | ||
| EV/EBITDA | 1.81 |
4.3 Compensation for Growth
A cheap valuation may be justified as OSE's earnings are expected to decrease with -42.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.7%
EPS Next 3Y-42.26%
5. Dividend
5.1 Amount
OSE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:OSE (8/29/2025, 7:00:00 PM)
6.13
-0.04 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.11%
Inst Owner ChangeN/A
Ins Owners24.93%
Ins Owner ChangeN/A
Market Cap140.44M
Analysts82.22
Price Target17.72 (189.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.3%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.58 | ||
| Fwd PE | 14.8 | ||
| P/S | 1.68 | ||
| P/FCF | 2.9 | ||
| P/OCF | 2.9 | ||
| P/B | 2.2 | ||
| P/tB | 7.09 | ||
| EV/EBITDA | 1.81 |
EPS(TTM)1.71
EY27.9%
EPS(NY)0.41
Fwd EY6.76%
FCF(TTM)2.11
FCFY34.44%
OCF(TTM)2.11
OCFY34.49%
SpS3.64
BVpS2.79
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.21% | ||
| ROE | 58.68% | ||
| ROCE | 42.16% | ||
| ROIC | 30.99% | ||
| ROICexc | 72.04% | ||
| ROICexgc | 5261.08% | ||
| OM | 52.42% | ||
| PM (TTM) | 44.88% | ||
| GM | N/A | ||
| FCFM | 57.96% |
ROA(3y)-5.73%
ROA(5y)-10.16%
ROE(3y)-31.94%
ROE(5y)-31.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 0.95 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 2.33% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.97% | ||
| Profit Quality | 129.16% | ||
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | 3.52 |
F-Score8
WACC6.91%
ROIC/WACC4.48
Cap/Depr(3y)5.62%
Cap/Depr(5y)12.68%
Cap/Sales(3y)4%
Cap/Sales(5y)3.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)245.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.06%
EPS Next Y-82.85%
EPS Next 2Y-63.7%
EPS Next 3Y-42.26%
EPS Next 5YN/A
Revenue 1Y (TTM)3646.52%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%-0.81%
Revenue Next Year-47.32%
Revenue Next 2Y-20.24%
Revenue Next 3Y10.24%
Revenue Next 5YN/A
EBIT growth 1Y287.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.82%
EBIT Next 3Y-64.61%
EBIT Next 5YN/A
FCF growth 1Y341.85%
FCF growth 3YN/A
FCF growth 5Y40.61%
OCF growth 1Y345.08%
OCF growth 3YN/A
OCF growth 5Y39.6%